Jozefina Casuscelli1, Maria F Becerra2, Brandon J Manley2, Emily C Zabor3, Ed Reznik4, Almedina Redzematovic5, Maria E Arcila6, Daniel M Tennenbaum7, Mazyar Ghanaat2, Mahyar Kashan2, Christian G Stief8, Maria Carlo5, Martin H Voss5, Darren R Feldman5, Robert J Motzer5, Yingbei Chen6, Victor E Reuter6, Jonathan A Coleman2, Paul Russo2, James J Hsieh9, Abraham Ari Hakimi10. 1. Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, Ludwig-Maximilians University, Munich, Germany. 2. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Pathology Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8. Department of Urology, Ludwig-Maximilians University, Munich, Germany. 9. Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hakimia@mskcc.org.
Abstract
BACKGROUND: Mutations in the promoter region of the TERT gene have been detected in a variety of cancers. These mutations can potentially lead to unlimited cell divisions and result in poor clinical prognosis. OBJECTIVE: To determine the role and relevance of TERT promoter region mutations in both clear cell (ccRCC) and non-clear cell (nccRCC) renal cell carcinoma using ultra-deep and whole-genome sequencing methods on primary tumor samples. DESIGN, SETTING, AND PARTICIPANTS: DNA from 281 kidney tumors (147 ccRCC and 134 nccRCC) was sequenced between 2013 and 2015, and clinical outcomes for these patients from a single institution were retrospectively analyzed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Differences in patient characteristics and mutational status were tested using Fisher's exact test for categorical variables and the Wilcoxon rank sum test for continuous variables. Survival times were estimated using the Kaplan-Meier method and differences were tested using the log-rank test. RESULTS AND LIMITATIONS: TERT mutations occurred in 12.2% of ccRCC and 10.4% of nccRCC cases. In >80% of the cases, mutations were located at C228T and were found to co-occur only rarely with other relevant RCC driver genes. The median follow-up among survivors overall was 2.5 yr (range 0.1-18.3). TERT promoter mutations were significantly associated with cancer-specific survival in ccRCC (hazard ratio 2.68, 95% confidence interval 1.19-6.01; p=0.013). In nccRCC, TERT mutations were significantly associated with larger tumors and metastatic development. Assessment of further relevant clinical associations was precluded in the nccRCC group by the heterogeneous and small sample size. CONCLUSIONS: Our data suggests that TERT mutational status reflects a distinct pathogenesis with an aggressive disease course in RCC. Stratifying patients with this unique tumorigenesis that leads to poor clinical outcomes could be a putative target for novel therapeutics. PATIENT SUMMARY: We show a previously unrecognized frequency of TERT promoter mutations in both clear cell and non-clear cell renal cell carcinoma. TERT promoter mutations were associated with some worse outcomes in patients with clear cell renal cell carcinoma.
BACKGROUND: Mutations in the promoter region of the TERT gene have been detected in a variety of cancers. These mutations can potentially lead to unlimited cell divisions and result in poor clinical prognosis. OBJECTIVE: To determine the role and relevance of TERT promoter region mutations in both clear cell (ccRCC) and non-clear cell (nccRCC) renal cell carcinoma using ultra-deep and whole-genome sequencing methods on primary tumor samples. DESIGN, SETTING, AND PARTICIPANTS: DNA from 281 kidney tumors (147 ccRCC and 134 nccRCC) was sequenced between 2013 and 2015, and clinical outcomes for these patients from a single institution were retrospectively analyzed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Differences in patient characteristics and mutational status were tested using Fisher's exact test for categorical variables and the Wilcoxon rank sum test for continuous variables. Survival times were estimated using the Kaplan-Meier method and differences were tested using the log-rank test. RESULTS AND LIMITATIONS: TERT mutations occurred in 12.2% of ccRCC and 10.4% of nccRCC cases. In >80% of the cases, mutations were located at C228T and were found to co-occur only rarely with other relevant RCC driver genes. The median follow-up among survivors overall was 2.5 yr (range 0.1-18.3). TERT promoter mutations were significantly associated with cancer-specific survival in ccRCC (hazard ratio 2.68, 95% confidence interval 1.19-6.01; p=0.013). In nccRCC, TERT mutations were significantly associated with larger tumors and metastatic development. Assessment of further relevant clinical associations was precluded in the nccRCC group by the heterogeneous and small sample size. CONCLUSIONS: Our data suggests that TERT mutational status reflects a distinct pathogenesis with an aggressive disease course in RCC. Stratifying patients with this unique tumorigenesis that leads to poor clinical outcomes could be a putative target for novel therapeutics. PATIENT SUMMARY: We show a previously unrecognized frequency of TERT promoter mutations in both clear cell and non-clear cell renal cell carcinoma. TERT promoter mutations were associated with some worse outcomes in patients with clear cell renal cell carcinoma.
Authors: João Vinagre; Ana Almeida; Helena Pópulo; Rui Batista; Joana Lyra; Vasco Pinto; Ricardo Coelho; Ricardo Celestino; Hugo Prazeres; Luis Lima; Miguel Melo; Adriana Gaspar da Rocha; Ana Preto; Patrícia Castro; Ligia Castro; Fernando Pardal; José Manuel Lopes; Lúcio Lara Santos; Rui Manuel Reis; José Cameselle-Teijeiro; Manuel Sobrinho-Simões; Jorge Lima; Valdemar Máximo; Paula Soares Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: John R Srigley; Brett Delahunt; John N Eble; Lars Egevad; Jonathan I Epstein; David Grignon; Ondrej Hes; Holger Moch; Rodolfo Montironi; Satish K Tickoo; Ming Zhou; Pedram Argani Journal: Am J Surg Pathol Date: 2013-10 Impact factor: 6.394
Authors: A Ari Hakimi; Irina Ostrovnaya; Boris Reva; Nikolaus Schultz; Ying-Bei Chen; Mithat Gonen; Han Liu; Shugaku Takeda; Martin H Voss; Satish K Tickoo; Victor E Reuter; Paul Russo; Emily H Cheng; Chris Sander; Robert J Motzer; James J Hsieh Journal: Clin Cancer Res Date: 2013-04-25 Impact factor: 12.531
Authors: Konstantin Salnikow; Olga Aprelikova; Sergey Ivanov; Sean Tackett; Monika Kaczmarek; Aldona Karaczyn; Herman Yee; Kazimierz S Kasprzak; John Niederhuber Journal: Carcinogenesis Date: 2008-04-01 Impact factor: 4.944
Authors: Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway Journal: Science Date: 2013-01-24 Impact factor: 47.728
Authors: Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke Journal: J Urol Date: 2002-12 Impact factor: 7.450
Authors: P Sivaramakrishna Rachakonda; Ismail Hosen; Petra J de Verdier; Mahdi Fallah; Barbara Heidenreich; Charlotta Ryk; N Peter Wiklund; Gunnar Steineck; Dirk Schadendorf; Kari Hemminki; Rajiv Kumar Journal: Proc Natl Acad Sci U S A Date: 2013-10-07 Impact factor: 11.205
Authors: So Yeon Won; Jun Ho Lee; Narae Lee; Yae Won Park; Sung Soo Ahn; Jinna Kim; Jong Hee Chang; Se Hoon Kim; Seung-Koo Lee Journal: PLoS One Date: 2022-10-20 Impact factor: 3.752
Authors: Renzo G DiNatale; Alejandro Sanchez; A Ari Hakimi; Ed Reznik; Julian Marcon; Ritesh R Kotecha; Sounak Gupta; Fengshen Kuo; Vladimir Makarov; Amar Sandhu; Roy Mano; Andrew W Silagy; Kyle A Blum; Daniel E Nassau; Nicole E Benfante; Michael V Ortiz; Maria I Carlo; Timothy A Chan; Robert J Motzer; Martin H Voss; Jonathan Coleman; Paul Russo; Victor Reuter Journal: Clin Cancer Res Date: 2020-03-27 Impact factor: 12.531
Authors: Renzo G DiNatale; Alexander N Gorelick; Vladimir Makarov; Kyle A Blum; Andrew W Silagy; Benjamin Freeman; Diego Chowell; Julian Marcon; Roy Mano; Alex Sanchez; Kyrollis Attalla; Stanley Weng; Martin Voss; Robert J Motzer; Paul Russo; Jonathan A Coleman; Victor E Reuter; Ying-Bei Chen; Timothy A Chan; Ed Reznik; Satish K Tickoo; A Ari Hakimi Journal: Eur Urol Focus Date: 2019-12-06
Authors: Sounak Gupta; Chad M Vanderbilt; Yun-Te Lin; Jamal K Benhamida; Achim A Jungbluth; Satshil Rana; Amir Momeni-Boroujeni; Jason C Chang; Tiffany Mcfarlane; Paulo Salazar; Kerry Mullaney; Sumit Middha; Ahmet Zehir; Anuradha Gopalan; Tejus A Bale; Ian Ganly; Maria E Arcila; Ryma Benayed; Michael F Berger; Marc Ladanyi; Snjezana Dogan Journal: J Mol Diagn Date: 2020-12-05 Impact factor: 5.568
Authors: Yao Yu; Dan Fan; Xinmao Song; Kaveh Zakeri; Linda Chen; Jung Kang; Sean McBride; C Jillian Tsai; Lara Dunn; Eric Sherman; Nora Katabi; Snjezana Dogan; Jennifer Cracchiolo; Marc Cohen; Jay O Boyle; Mark Lee; Cristina Valero; Jingming Wang; Richard Wong; Luc Morris; Nadeem Riaz; Nancy Lee Journal: JCO Precis Oncol Date: 2021-08-05
Authors: Nirmish Singla; Zhiqun Xie; Ze Zhang; Ming Gao; Qurratulain Yousuf; Oreoluwa Onabolu; Tiffani McKenzie; Vanina Toffessi Tcheuyap; Yuanqing Ma; Jacob Choi; Renee McKay; Alana Christie; Oscar Reig Torras; Isaac A Bowman; Vitaly Margulis; Ivan Pedrosa; Christopher Przybycin; Tao Wang; Payal Kapur; Brian Rini; James Brugarolas Journal: JCI Insight Date: 2020-04-09
Authors: Nazli Dizman; Yung Lyou; Nicholas Salgia; Paulo Gustavo Bergerot; JoAnn Hsu; Daniel Enriquez; Tyler Izatt; Jeffrey M Trent; Sara Byron; Sumanta Pal Journal: J Immunother Cancer Date: 2020-07 Impact factor: 13.751
Authors: Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre Journal: Genes (Basel) Date: 2018-05-03 Impact factor: 4.096